[New approaches for the development of anti-Alzheimer's disease drugs based on the cholinergic hypothesis and amyloid hypothesis].
Sugimoto
Hachiro
H
hsugimot@pharm.kyoto-u.ac.jp
D000109:Acetylcholine / Q000502:physiology; D000110:Acetylcholinesterase / Q000502:physiology; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000209:etiology*; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors* / Q000502:physiology; D016229:Amyloid beta-Peptides / Q000378:metabolism* / Q000633:toxicity; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D002794:Choline / Q000031:analogs & derivatives / Q000502:physiology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D013654:Taurine / Q000031:analogs & derivatives
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D002800:Cholinesterase Inhibitors; D004791:Enzyme Inhibitors; D013654:Taurine; C017100:butyrylcholine; C001355:tramiprosate; D000110:Acetylcholinesterase; D053829:Amyloid Precursor Protein Secretases; D002794:Choline; D000109:Acetylcholine